INDICATIONS  : Fusion Plus TM is indicated for the treatment of Iron defficiency anemia and folate defficiency as in extended convalescence ,menorrhagia, pregnancy, puberty, excessive blood loss and advanced age.  Also for treatment of condition in which Iron defficiency and Vitamine C defficiency occur together along with a defficient intake or increased need for B-complex vitamins in chronic and acute illness as well as  cases of metabolic stress and convalescence 

CONTRADICTIONS: Fusion Plus TM is contraindicated in patients with a known hypersensitivity to any of its ingredients; also, all iron compounds are contraindicated in patients with hemosiderosis, hemochromatosis, or haemolytic anemias. It is also contradicated in patients suffering from pernicious anemia as folic acid may obscure its signs and symptoms.

Ferrous Fumarate and Polysaccharide Iron Complex (PIC): All Fusion Plus TM products include a unique patented source of iron, e.g. Ferrous Fumarate and Polysaccharide Iron Complex (U.S. Patent No. 11/243,043 Pending). “An increase in tolerability is observed with the (patended formulation) and is believed to occur as the result of distributing the total iron content in the composition among compounds that provide iron to the patient’s blood stream via two different mechanisms. The ferrous salts are readily absorbed in the upper gut, by direct dissolution and absorption of the ferrous iron by the bloodstream. However, the iron available from PIC is absorbed in the lower gut, via an active protein transport mechanism”.
Clinical Studies: Picinni, L.-Ricciotti, M. 1982. Therapeutic effectiveness of an iron-polysaccharide complex in comparison with iron fumarate in the treatment of iron deficiency anemias: PANMINERVA MEDICA-EUROPA MEDICA, Vol. 24, No.3. pp.213-220 (July-September 1982).

Folic Acid: Folic acid is one of the important hematopoietic agents necessary for proper regeneration of the blood-forming elements and their function. Additionally, folic acid increases jejuna glycolytic enzymes and is involved in the desaturation and hydroxylation of long-chain fatty acids in the brain. A deficiency in folic acid results in megaloblastic anemia.

WARNING: Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where Vitamin B12 is deficient.

PRECAUTIONS: Folic acid in doses above 0.1 mg – 0.4 mg daily may obscure  pernicious anemia, in that haematological remission can occur while neurological manifestations remain progressive. The use of this product by immunocompromised patients or treatment of any disorder must be medically supervised by a physician

Consult package literature for full prescription information. You should contact your healthcare provider for medical advice about adverse events. To report a serious adverse event, contact US Pharmaceutical Corporation, P.O. Box 360465, Decatur, GA 30036. Marketed by US Pharmaceutical Corporation

CAUTION: Rx only.

Store at controlled room temperature 15°C to 30°C (59° to 86° F). Keep in cool, dry place. 

DOSAGE AND ADMINISTRATION: Adults (persons over 12 years of age), one (1) capsule daily, between meals, or as prescribed by a physician. Do not exceed recommended dosage. Do not administer to children under the age of 12.

HOW SUPPLIED: Fusion Plus TM are Pearl Red opaque Vcaps® capsules imprinted “US” logo and “F Plus” in white. Child resistant bottles of 30 capsules, NDC# 52747-502-30. Dispense in a tight, light-resistant container as defined in the USP/NF with a child resistant closure.

Iron / Folic acid / Vitamin / Probiotic Supplement Capsules